My long-term career goal is to optimize the health outcomes of infant and children living in resource limited settings. The current focus of my research is the optimization of treatment outcomes of children born with human immunodeficiency virus (HIV) infection. I continue to work broader issues of maternal child health through an NGO that I co-founded, now called Global Strategies. I am interested in advancing new agents for the treatment of children and infants living with HIV. I serve as vice-chair of the NIH/DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children that publishes treatment guidelines for children in the USA, and an advisor to the Pediatric AIDS Working Group at the World Health Organization, Within the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT), I serve as vice-chair of the Treatment Scientific Committee and co-chair of P1093, the protocol establishing dosing and safety of Dolutegravir in children. I have also become interested in the potential impact of very early treatment on outcomes in perinatally infected infants. I am an investigator on the IMPAACT P1115 that is enrolling early-treated in utero HIV-infected infants from network sites through the world and treating with an aggressive 4 drug regimen. I am also the principal investigator of the NICHD-funded study called The Treating Infants Early Study (TIES), which that enrolling infants who start treatment within the first weeks of life to look at safety, virologic decay, latent reservoir establishment. In Africa, I have been involved several trials looking that treatment of malaria and HIV in children, and now lead pediatric studies in the SEARCH trial, which tests strategies to diagnosis and successfully treat individuals living with HIV in rural Kenya and Uganda. I continue to work closely with our NGO Global Strategies continues to innovate new ways to optimize HIV and neonatal care in limited resource settings.